WAVE 2021 - SCHEUDLE

21 March 2021

08:55

Welcome from OWA

09:00 21 March 2021

Day 2 - Session 1: Retinal & OCT - 2 Presentations

Session - Diabetes, Imaging Modalities/Diagnostic Equipment, Retinal Disease (Other) - 60.0 mins - Plenary Room , Plus Virtual Stream
A 1hr grouped themed session on Retinal & OCT presented by Bang Bui's two 30 minute lectures

09:00

Future Clinical Uses of OCT for Neurodegenerative Diseases

Bang Bui

Summary: Increasingly, neuronal changes and pathology causing proteins that herald a number of central nervous system diseases are also being found in the eye. The ease with which the retina can be accessibility with non-invasive imaging makes it a potentially useful location to screen for neurodegenerative diseases. The prospect that specific signs of common conditions such as Alzheimer's disease and Parkinson's disease can be detected using optical coherence tomography is an exciting avenue of clinical application. This talk will summarise the latest developments in this area.

Learning Objective: To better understand the retinal manifestations of common neurodegenerative diseases and how this might manifest in changes the retina detectable using optical coherence tomography.

Assessment: There are no MCQS for this lecture.

09:30

OCT Angiography Applications & Diabetic Eye Disease

Bang Bui

Summary: Whilst we are well trained to clinically detect sign of diabetes induced damage to the retinal blood vessels, sub-clinical changes to. However, damage to the retinal capillaries may be occurring much earlier. The advent of optical coherence tomography angiography now allows us to quantify changes to the capillary network and holds the promise for better understanding of diabetic eye disease pathogenesis as well as new tools for earlier disease detection.

Learning Objective: To gain an understanding of how diabetes impacts the microvasculature and how this can be detected clinically using OCT angiography.

Assessment: There are 5 optional MCQS for this lecture.

10:00 **21 March 2021**

Day 2 - Session 2: Contact Lens - 2 Presentations

Session - Contact Lenses, Cornea/Conjunctiva - 60.0 mins - Plenary Room , Plus Virtual Stream
A 1hr grouped session with two 30 minute presentations from David Foresto.

10:00

Latest in Evidenced Based Keratoconus Management

David Foresto

Summary: At the same time as scleral lenses have revolutionised the vision correction of keratoconus patients, a plethora of new surgical techniques are being offered. This lecture will help practitioners understand the evidence levels of the current options and assist optometrists to make ethical decisions in the management of their keratoconus patients.

Learning Objective:
To understand the varying levels of evidence behind forms of vision correction and surgical intervention for keratoconus patients.

Assessment: There are no MCQS for this lecture.

10:30

Don't Fall for These Contact Lens Traps

David Foresto

Summary: With the multitude of contact lens options and marketing promises, it is very easy for practitioners to mistakenly go down the wrong path when commencing a contact lens fit.
This lecture will help practitioners avoid common contact lens fitting mistakes and help optometrists to identify when patient expectations are inconsistent with currently available technology.

Learning Objective:
To identify when contact lens technology and patient expectations are incompatible before commencing a contact lens fit.

Assessment: There are no MCQS for this lecture.

11:00 - 11.30 **21 March 2021**

Morning Tea Day 2

21 March 2021

Day 2 - Session 3: Glaucoma - 3 Presentations

Session - Glaucoma, Therapeutics - 90.0 mins - Plenary Room , Plus Virtual Stream
Three 30 minute presentations on Glaucoma from Jack Phu & Dr Rhuju Mehta.

11:30

Glaucoma or Not Glaucoma - That is the Question (T)

Jack Phu

Summary: Mimickers of glaucoma can range considerably from relatively benign anomalies of the optic nerve configuration to diagnoses that are potentially far more sinister. This lecture will present strategies for distinguishing between glaucoma and non-glaucomatous causes of optic atrophy.

Learning Objectives:

1. Be able to recognise non-glaucomatous visual field defects and action relevant further investigations
2. Apply multimodal imaging techniques to distinguish glaucoma and non-glaucomatous optic atrophy
3. Understand the limitations of cross-sectional optical coherence tomography parameters in glaucoma diagnosis

Assessment: There are 5 optional MCQS with this lecture.

12:00

Pre-Perimetric Glaucoma (T)

Jack Phu

Summary: Are we diagnosing glaucoma too early? Do all patients with pre-perimetric glaucoma require treatment? When and how should we treat patients with pre-perimetric glaucoma? This lecture will review some of the evidence underpinning the decision making processes in pre-perimetric glaucoma.

Learning Objectives:

1. Understand the diagnostic process of pre-perimetric glaucoma
2. Understand the natural history and progression of glaucoma
3. Understand the clinical trials for treatment of pre-perimetric glaucoma

Assessment: There are 5 optional MCQS with this lecture.

12:30

Managing Adverse Effects of Glaucoma Medications (T)

Doctor Rhuju Mehta

Summary: Topical glaucoma drops are usually a lifelong commitment and may result in unwanted ocular and/or systemic side effects. This talk will highlight how to identify and minimise these adverse effects

Learning objective: to recognise and understand how to minimise adverse effects from topical glaucoma drops.

Assessment: There are 5 optional MCQS with this lecture.

13:00

21 March 2021

Day 2 - Session 4: Nutrition - 1 Presentation

Session - Nutrition - 30.0 mins - Plenary Room , Plus Virtual Stream
A single 30 minute lecture from Associate Professor Laura Downie on nutrition and your eyes.

13:00

Nutrition & Eye Health: Eating for Healthy Eyes

Associate Professor Laura Downie

Summary: Diet is a key lifestyle factor that can have long-term effects on ocular health. This lecture will review what is known about how optometrists engage with their patients to ask about diet and nutritional supplement behaviours, as well as the advice provided in relation to nutrition and eye health. The presentation will also provide an overview of evidence relating to the use of omega-3 fatty acid supplements for modulating eye health and treating ocular conditions.

Learning Objective: To understand how diet and nutritional supplementation affect eye health.

Assessment: There are no MCQS with this lecture.

13:30 - 14.30 **21 March 2021**

Lunch Break Day 2

Exhibitor Bump out 14.30 Sunday 21st March

14:30 **21 March 2021**

Day 2 - Session 5: Glaucoma - 2 Presentations

Session - Glaucoma, Therapeutics - 60.0 mins - Plenary Room , Plus Virtual Stream
A 1hr session featuring two 30 minute lectures from Jack Phu.

14:30

An Update on Recent Glaucoma Studies (T)

Jack Phu

Summary: What's the optimal first line treatment for glaucoma? How should we perform gonioscopy and when is prophylactic treatment indicated in angle closure spectrum disease? How often should I be doing visual fields? These questions will be addressed using the most recent literature so that delegates will be equipped with evidence for best clinical practice.

Learning Objectives:

1. Understand the role of selective laser trabeculoplasty for treatment of glaucoma
2. Identify suitable patients for prophylactic treatment for angle closure spectrum disease
3. Apply best practice and new perimetric paradigms to optimise functional testing in glaucoma

Assessment: There are 5 optional MCQS with this lecture.

15:00

Recent & Emerging Topical Therapies for Glaucoma (T)

Jack Phu

Summary: Rarely are there significant paradigms shifts in therapeutic treatment modalities for glaucoma. Recent developments have eventuated in market penetration by new glaucoma medications and treatment strategies. This lecture will review some recent and emerging topical therapies for glaucoma.

Learning Objectives:

1. Compare and contrast preserved and non-preserved topical glaucoma therapy
2. Understand the actions, efficacy and safety of latanoprostene bunod
3. Understand the actions, efficacy and safety of netarsudil

Assessment: There are 5 optional MCQs for this lecture.

15:30 **21 March 2021**

Day 2 - Session 6: Dry Eye/ OSD

Session - Cornea/Conjunctiva, Dry Eye/Tear Film, Therapeutics - 60.0 mins - Plenary Room , Plus Virtual Stream
Final lectures of the conference presented by Associate Professor Laura Downie on Dry Eye / OSD.

15:30

Dry Eye Disease: Diagnostic Myths & Realities

Associate Professor Laura Downie

Summary: This lecture will delve into the clinical intricacies of accurately identifying dry eye disease, and the techniques available to subtype dry eye disease. The presentation will also discuss emerging technologies for identifying tear film dysfunction in eye care practice.

Learning Objective: To understand current best practice for diagnosing and subtyping dry eye disease

Assessment: There are no MCQS with this lecture.

16:00

New Insights into the Treatment of Ocular Surface Disease (T)

Associate Professor Laura Downie

Summary: Ocular surface disease is one of the most frequent presentations to optometry practice. Whilst conventional therapies often focus on reducing patient symptomatology, novel therapeutics are being developed to target disease pathophysiology. This lecture will provide a contemporary update on the management of treatment of different types of ocular surface disease.

Learning Objective: To be knowledgeable of current and emerging approaches for treating ocular surface disease

Assessment: There are 5 optional MCQS for this lecture.

16:30 **21 March 2021**

Conference Conclusions